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Abstract
Background: Smac/Diablo is a recently identified protein that is released from mitochondria after
apoptotic stimuli. It binds IAPs, allowing caspase activation and cell death. In view of its activity it
might participate in carcinogenesis. In the present study, we analyzed Smac expression in a panel
of cervical cancer patients.
Methods: We performed semi quantitative RT-PCR on 41 cervical tumor and 6 normal tissue
samples. The study included 8 stage I cases; 16 stage II; 17 stage III; and a control group of 6 samples
of normal cervical squamous epithelial tissue.
Results: Smac mRNA expression was below the detection limit in the normal cervical tissue
samples. In contrast, 13 (31.7%) of the 41 cervical cancer biopsies showed detectable levels of this
transcript. The samples expressing Smac were distributed equally among the stages (5 in stage I, 4
in stage II and 4 in stage III) with similar expression levels. We found no correlation between the
presence of Smac mRNA and histology, menopause, WHO stage or disease status.
Conclusions: Smac is expressed de novo in a subset of cervical cancer patients, reflecting a possible
heterogeneity in the pathways leading to cervical cancer. There was no correlation with any clinical
variable.
Background
Apoptosis is an evolutionarily conserved biological proc-
ess that plays a fundamental role in development and tis-
sue homeostasis in metazoans [1]. This type of cell death
is executed by a family of proteases known as caspases [2].
There are two well-characterized apoptotic pathways that
converge in caspase activation: the death receptor path-
way and the mitochondrial pathway [3]. Inhibitors of
Apoptosis Proteins (IAPs) are the most important regula-
tors of caspases. These proteins inhibit caspase activation,
thus preventing the induction of apoptosis [4]. In cells
undergoing apoptosis, IAPs are inactivated by interaction
with proteins containing the so-called IBM (IAP-binding
motif) [4,5].
One IBM protein is the recently identified Smac/DIABLO
[6,7]. Smac resides in the mitochondrial intermembrane
space in healthy cells but is released into the cytosol dur-
ing apoptosis, where it interacts with IAPs and disrupts
their ability to bind caspases [8]. Smac is expressed ubiq-
uitously, with high expression in adult testis, heart, liver,
kidney, spleen, prostate and ovary and low expression in
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brain, lung, thymus, and peripheral blood leukocytes [9].
It is encoded in a nuclear gene and is post-translationally
imported into the mitochondria via a targeting sequence
in its amino terminus. Removal of this signal generates a
mature polypeptide with the IBM at the amino terminal
end [10]. Smac interacts with all mammalian IAPs exam-
ined so far: XIAP, cIAP-1, cIAP-2, survivin and ML-IAP
[6,7,11,12]. The structure of the Smac-XIAP complex has
been studied by X-ray crystallography [13] and high-reso-
lution NMR [14]; it appears that the tetrapeptide AVPI is
indispensable for the formation of this complex.
IAPs are highly expressed in human tumor cells [15-17],
contributing to the intrinsic resistance of these cells to
Table 1: Smac mRNA expression levels and clinicopathological factors in cervical cancer
Sample Age Stage Histology of tumor Menopause Current status Smac/GAPDH
Control 42 - Menopause Disease-free 0
Control 33 - Pre-menopause Disease-free 0
Control 28 - Pre-menopause Disease-free 0
Control 44 - Menopause Disease-free 0
Control 47 - Menopause Disease-free 0
Control 35 - Pre-menopause Disease-free 0
1 46 I Adenocarcinome Menopause Disease-free 0
2 52 I Squamous cell Post-menopause Disease-free 76.01
3 49 I Squamous cell Menopause Disease 203.36
4 44 I Squamous cell Pre-menopause Disease-free 0
5 65 I Squamous cell Post-menopause Disease-free 0
6 67 I Squamous cell Post-menopause Disease-free 86.53
7 47 I Squamous cell Menopause Disease-free 65.3
8 34 I Squamous cell Pre-menopause Disease-free 66.45
9 49 II Squamous cell Menopause Disease-free 78.44
10 63 II Squamous cell Post-menopause Disease-free 0
11 38 II Squamous cell Menopause Disease-free 0
12 48 II Squamous cell Menopause Disease-free 0
13 55 II Squamous cell Post-menopause Disease-free 0
14 35 II Squamous cell Pre-menopause Disease-free 166.25
15 66 II Squamous cell Post-menopause Disease 0
16 52 II Squamous cell Post-menopause Disease 0
17 80 II Squamous cell Post-menopause Disease 0
18 70 II Squamous cell Post-menopause Disease-free 0
19 65 II Squamous cell Post-menopause Disease 0
20 39 II Squamous cell Pre-menopause Disease 70.42
21 57 II Squamous cell Post-menopause Disease-free 55.45
22 37 II Squamous cell Pre-menopause Disease-free 0
23 59 II Squamous cell Post-menopause Disease 0
24 36 II Squamous cell Pre-menopause Disease 0
25 33 III Adenocarcinome Pre-menopause Dead 0
26 50 III Adenocarcinome Post-menopause Dead 0
27 60 III Squamous cell Post-menopause Disease-free 0
28 64 III Adenocarcinome Post-menopause Dead 0
29 80 III Squamous cell Post-menopause Dead 0
30 52 III Squamous cell Post-menopause Disease-free 173.96
31 56 III Squamous cell Post-menopause Disease-free 0
32 70 III Squamous cell Post-menopause Disease-free 81.5
33 72 III Adenosquamous Post-menopause Dead 0
34 33 III Squamous cell Pre-menopause Disease 0
35 82 III Adenocarcinome Post-menopause Disease 0
36 48 III Squamous cell Menopause Disease-free 0
37 32 III Squamous cell Pre-menopause Disease 98.59
38 48 III Squamous cell Menopause Disease 0
39 36 III Adenosquamous Pre-menopause Disease 0
40 52 III Squamous cell Post-menopause Disease-free 0
41 67 III Squamous cell Post-menopause Disease-free 88.95BMC Cancer 2004, 4:84 http://www.biomedcentral.com/1471-2407/4/84
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endogenous death receptor-induced apoptosis and conse-
quently to chemotherapy [18]. For this reason, peptides
mimicking the action of Smac have been generated and
analyzed. Four publications to date have shown promis-
ing effects of these Smac peptides in vitro and in vivo; how-
ever, further studies are required prior to clinical testing
[19-22].
Recently, Sekimura and colleagues found that Smac
expression was significantly lower in primary lung cancers
than in normal tissue [23]; patients with lower Smac
mRNA levels had worse prognoses. These results indicate
that Smac expression may play a role in the progression of
primary lung cancer and may be useful for prognosis [23].
However, Smac expression has not been analyzed in other
tumors. In view of the possible role of Smac in cervical
carcinogenesis and its potential as a therapeutic target, we
have investigated the expression of this apoptotic protein
in cervical cancer patients.
Methods
Cell lines and tumor samples
Cervical cancer cell lines (HeLa, SiHa, CaSki and CaLo)
were obtained from ATCC and cultured as monolayers in
Dulbecco Modified Eagle's Medium (DMEM) containing
10% (V/V) fetal bovine serum (GIBCO, Bethesda, MD,
USA) at 37°C in a humidified atmosphere of 5% (V/V)
CO2.
Forty-one cervical cancer samples were obtained from the
Instituto Nacional de Cancerologia of Mexico. Written
consent was obtained from patients before the samples
were collected. Tumors were staged according to the Inter-
national Gynecology and Obstetric Federation (FIGO)
system. The samples comprised 8 at stage IB, 16 at stage
IIB and 17 at stage IIIB; and a control group comprising 6
samples of normal cervical squamous epithelial tissue
(Table 1). The control samples were derived from hyster-
ectomy specimens from patients with uterine myomato-
sis. Only samples with normal pathological reports were
included.
Histology
Histopathological grading was done according to the
WHO (World Health Organization) classification system
(Table 1).
RNA isolation and RT-PCR
RNA extraction and RT-PCR analysis were performed as
described previously [24]. Briefly, total RNA was extracted
from cultured cells, tumors and non-neoplastic tissue
samples with Trizol reagent (Invitrogen) following the
manufacturer's protocol. RNA purity was confirmed by
the 260/280 nm absorbance ratio and its integrity was
established with agarose gels. Total RNA (2 µg) was
reverse-transcribed in a final 20 µl reaction volume using
15 U ThermoScript reverse transcriptase, 2.5 × RT Buffer
and random hexamers (ThermoScript RT-PCR, Invitro-
gen). The RT-PCR steps were 25°C for 10 min, 50°C for
50 min and 85°C for 5 min. Smac and GAPDH mRNA
PCR reactions contained 0.25 µl Amplitaq gold polymer-
ase (Applied Biosystems, ROCHE), 2.5 µl 10 × reaction
buffer, 0.5 µl dNTP mix 10 mM, 1 µl sense primer 10 µM,
1 µl anti-sense primer 10 µM and 1 µl cDNA in 25 µl final
volume. The Smac primers were: sense 5' GCGCGGATC-
CATGGCGGCTCTGAAGAGTTG 3' and anti-sense 5'
AGCTCTCTAGACTCAGGCCCTCAATCCTCA 3'. The
GAPDH primers were: sense 5' CCCCTTCATTGACCT-
CAACT 3' and antisense 5' TTGTCATGGATGACCTTGGC
3'.
The PCR cycle parameters for Smac were: 10 min enzyme
activation at 95°C followed by 3 cycles of 30 s at 95°C
and 2 min at 72°C, then 30 cycles of 30 s at 95°C and 30
s at 68°C, and finally 5 min at 72°C. The corresponding
parameters for GAPDH were: 10 min enzyme activation at
95°C followed by 25 cycles of 30 s at 95°C, 30 s at 60°C
and 30 s at 72°C. The products were electrophoresed on
1% agarose gels and stained with ethidium bromide.
Smac mRNA data were expressed as ratios between the
densitometric values (Scion Image software) of Smac gene
Smac/Diablo mRNA expression in cervical cancer cell lines Figure 1
Smac/Diablo mRNA expression in cervical cancer cell lines. 
Upper panel: RT-PCR analysis of HeLa, SiHa, CasKi and CaLo 
cervical cancer cell lines. To the left molecular weight marker 
(100 bp ladder, Invitrogen). Lower panel: RT-PCR of 
GAPDH, used as a mRNA load control.BMC Cancer 2004, 4:84 http://www.biomedcentral.com/1471-2407/4/84
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expression. The PCR products were normalized to the
amplified GAPDH, the internal reference gene. Gene
expression measurements were repeated at least twice.
Statistical analysis
To detect a correlation between pathological tumor
parameters and normalized Smac expression we used
ANOVA (stage, current disease and menopause status)
and chi square tests (stage, histology of tumors, meno-
pause and current status). Kaplan-Meier curves for status
were generated and log rank was used to test for differ-
ences. The mean follow-up was 14.7 months. The statisti-
cal package Intercooled Stata 7.0 was used for analyses
and statistical significance was accepted when the p value
was less than 0.05.
Results
To ascertain whether Smac is expressed in cervical cancer
we performed semiquantitative RT-PCR analyses on a
panel of cervical cancer lines, including HeLa, SiHa, CasKi
and CaLo cells. As shown in Figure 1, the HeLa and CasKi
lines contained Smac mRNA, but very low levels were
observed in SiHa and CaLo cells.
Next, we measured Smac mRNA levels using the same
approach in 41 cervical tumor and 6 normal cervical sam-
ples. To ensure accurate determinations and to verify
equal RNA input, GAPDH mRNA was amplified simulta-
neously. Figure 2 shows a representative panel of results,
which are given in Tables 1 and 2. Unexpectedly, Smac
mRNA was below the detection limit in normal cervical
samples. In contrast, as expected from the cell line data,
13 (31.7%) of the 41 cervical cancer biopsies contained
detectable levels of this transcript. The samples expressing
Smac were distributed equally among the stages (5 in
stage I, 4 in stage II and 4 in stage III). We found no signif-
icant correlation between Smac mRNA level and histol-
ogy, menopause, clinical stage or disease status (Table 2).
When the Smac expression levels in the tumor samples
were analyzed, there were no significant differences
between clinical stages (Figure 3), menopause status (Fig-
ure 4) or disease status (Figure 5). Similarly, a survival
analysis of the patients showed no statistical differences
Table 2: Smac positivity in cervical cancer tumor samples.
Variable No. Patients (n = 41) Smac Positive (n = 13) Smac Negative (n = 28) P
Age 53.36 (32–82) 50 54.92 0.3
Stage
I B853
IIB 16 4 12 0.11
IIIB 17 4 13
Histology of tumors
Squamous cell 34 13 21
Adenocarcinoma 5 0 5 0.14
A d e n o s q u a m o u s 202
Menopausal status
Pre-Menopause 12 5 7
Menopause 6 2 4 0.64
Post-Menopause 23 6 17
Current status
Disease free 21 9 12
Diseased 15 4 11 0.15
D e a d 505
Smac/Diablo mRNA expression in cervical cancer patients Figure 2
Smac/Diablo mRNA expression in cervical cancer patients. 
Upper panel: RT-PCR analysis of Smac/Diablo mRNA. To the 
left molecular weight marker (100 bp ladder, Invitrogen). 
Clinical stage is showed at the top of the panel: C: control 
samples, 1, 2 and 3, clinical stages. Lower panel: RT-PCR of 
GAPDH, used as a load control.BMC Cancer 2004, 4:84 http://www.biomedcentral.com/1471-2407/4/84
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between patients expressing or not expressing Smac
mRNA (Figure 6).
Discussion
Tumors proliferate beyond the constraints that limit
growth in normal tissue. Therefore, the resistance of
tumor cells to apoptosis is an essential feature of carcino-
genesis. This has been confirmed by the finding that
deregulated proliferation alone is not sufficient for tumor
formation because there is concomitant induction of cell
death [25]. Overexpression of growth-promoting onco-
genes such as c-Myc sensitize cells to apoptosis [26]. Thus,
tumor progression requires the expression of anti-apop-
totic proteins or the inactivation of essential pro apoptotic
proteins [27,28]. Indeed, it has been shown that survivin,
a member of the Inhibitor of Apoptosis Protein (IAP)
family, is upregulated in some tumors [29], correlating
with prognosis [30,31].
Smac is a recently identified proapoptotic protein that
interacts with and inhibits several IAPs, including survivin
[6,11]. It has been shown that Smac mRNA levels in
tumor tissues are significantly lower than in normal tis-
sues [23]. Patients with lower Smac mRNA levels have
worse prognoses. These results indicate that Smac expres-
sion may play a role in the progression of primary lung
Smac expression levels versus clinical stage of cervical cancer  samples Figure 3
Smac expression levels versus clinical stage of cervical cancer 
samples. Graph shows median, upper and lower quartiles. P 
value testing the significance of the difference by ANOVA.
Smac expression levels versus menopausal status of cervical  cancer samples Figure 4
Smac expression levels versus menopausal status of cervical 
cancer samples. Graph shows median, upper and lower quar-
tiles. P value testing the significance of the difference by 
ANOVA.
Smac expression versus disease status of cervical cancer  samples Figure 5
Smac expression versus disease status of cervical cancer 
samples. Graph shows median, upper and lower quartiles. P 
value testing the significance of the difference by ANOVA.BMC Cancer 2004, 4:84 http://www.biomedcentral.com/1471-2407/4/84
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cancer, as expected by the known role of this protein in
cell death induced by chemotherapeutic drugs. Unexpect-
edly, we found that during cancer progression, some cer-
vical tumors express this protein de novo.
Unfortunately, we found no correlation between Smac
expression and any clinical variable. This could be attrib-
uted to differences in tissue expression of IAPs, which are
reported to have different binding affinities for Smac. On
the other hand, alternative IAPs such as the recently iden-
tified Omi/Htra2 [32] might play an important tissue- or
tumor-specific role. This is supported by the recent report
of a null phenotype in Smac-deficient mice, in which a
role for other IAP inhibitory proteins is suspected [33].
Cancer treatment by chemotherapy and γ-irradiation kills
cells primarily by the induction of apoptosis. However,
few tumors are wholly sensitive to these therapies, and the
development of resistance to therapy is an important clin-
ical problem. Failure to activate the apoptotic programme
represents an important mode of drug resistance in tumor
cells [34]. Modulation of the key elements in apoptotic
signaling should directly influence therapy-induced
tumor-cell death. Indeed, it has recently been suggested
that peptides mimicking the Smac amino-terminus could
be a novel therapeutic weapon [19]. Tumors with low or
null Smac expression, such as the ones reported in this
study, could be more susceptible to this approach.
Conclusions
During cervical cancer progression, a subset of tumors
express the apoptotic protein Smac de novo. This finding
contrasts with a previous report for lung cancer [23],
underlining the notion that downregulation or even
expression of Smac could be dispensable for tumor pro-
gression, at least in cervical cancer. This could be because
other mitochondrial molecules such as Omi might
substitute for its known proapoptotic function. There was
no correlation between Smac expression and any clinical
variable.
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